Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction

Journal of Medicinal Chemistry

Volumn 52, Issue 24, 2009, Pages 7970-7973

  Yu, Shanghai ^a   Qin, Dongguang ^a   Shangary, Sanjeev ^a   Chen, Jianyong ^a   Wang, Guoping ^a   Ding, Ke ^a   McEachern, Donna ^a   Qiu, Su ^a   Nikolovska Coleska, Zaneta ^a   Miller, Rebecca ^a   Kang, Sanmao ^b   Yang, Dajun ^b   Wang, Shaomeng ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Ascenta Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IRINOTECAN; MI 122; MI 126; MI 142; MI 147; MI 188; MI 219; MI 220; MI 221; MI 63; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; TUMOR CELL; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BONE NEOPLASMS; CELL LINE, TUMOR; DRUG DESIGN; HCT116 CELLS; HUMANS; INDOLES; MICE; MORPHOLINES; OSTEOSARCOMA; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RATS; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73249140963     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm901400z     Document Type: Article

References (22)

1. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
2. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 2000, 408, 307-310.
3. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
4. Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7 (7A), 1126-1132.
5. Chèene, P. Inhibiting the p53 - MDM2 interaction: an important target for cancer therapy. Nat. Rev Cancer. 2003, 3, 102-109.
6. Kussie, P. H.; Gorina, S.; Marechal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of theMDM2oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
7. Garcia-Echeverria, C.; Chene, P.; Blommers, M. J. J.; Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 2000, 43, 3205-3208.
8. Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small molecule antagonists of MDM2. Science 2004, 303, 844-848.
9. Ding, K.; Lu, Y.; Nikolovska-Koleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Roller, P. P.; Tomita, Y.; Deschamps, J. R.; Wang, S. Structure-based design of potent non-peptideMDM2inhibitors. J. Am. Chem. Soc. 2005, 127, 10130-10131.
10. Ding, K; Lu, Y; Nikolovska-Coleska, Z; Wang, G; Qiu, S; Shangary, S; Gao, W; Qin, D; Stuckey, J; Krajewski, K; Roller, P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49, 3432-3435.
11. Shangary, S; Qin, D; McEachern, D; Liu, M; Miller, R. S.; Qiu, S; Nikolovska-Coleska, Z; Ding, K; Wang, G; Chen, J; Bernard, D; Zhang, J; Lu, Y; Gu, Q; Shah, R. B.; Pienta, K. J.; Ling, X; Kang, S; Guo, M; Sun, Y; Yang, D; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 3933-39388.
12. Saddler, C.; Ouillette, P.; Kujawski, L.; Shangary, S.; Talpaz, M.; Kaminski, M.; Erba, H.; Shedden, K.; Wang, S.; Malek, S. N. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008, 111, 1584-1593.
13. Shangary, S.; Ding, K.; Qiu, S.; Nikolovska-Coleska, Z.; Bauer, J. A.; Liu, M.; Wang, G.; Lu, Y.; McEachern, D.; Bernard, D.; Bradford, C. R.; Carey, T. E.; Wang, S. Reactivation of p53 by a specificMDM2antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther. 2008, 7, 1533-1542.
14. Grasberger, B. L.; Lu, T.; Schubert, C.; Parks, D. J.; Carver, T. E.; Koblish, H. K.; Cummings, M.D.; LaFrance, L. V.; Milkiewicz, K. L.; Calvo, R. R.; Maguire, D.; Lattanze, J.; Franks, C. F.; Zhao, S.; Ramachandren, K.; Bylebyl, G. R.; Zhang, M.; Manthey, C. L.; Petrella, E. C.; Pantoliano, M. W.; Deckman, I. C.; Spurlino, J. C.; Maroney, A. C.; Tomczuk, B. E.; Molloy, C. J.; Bone, R. F. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J. Med. Chem. 2005, 48, 909-912.
15. Lu, Y; Nikolovska-Coleska, Z; Fang, X; Gao, W; Shangary, S; Qiu, S; Qin, D; Wang, S. Discovery of a nanomolar inhibitor of the human murine double minute 2(MDM2)-p53 interaction through an integrated, virtual database screening strategy. J. Med. Chem. 2006, 49, 3759-3762.
16. Galatin, P. S.; Abraham, D. J. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J. Med. Chem. 2004, 47, 4163-4165.
17. Bowman, A. L.; Nikolovska-Coleska, Z.; Zhong, H.; Wang, S.; Carlson, H. A. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J. Am. Chem. Soc. 2007, 129, 12809-12814.
18. Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; K€allblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M.; Lunec, J. Smallmolecule inhibitors of theMDM2-p53 protein-protein interaction based on an isoindolinone scaffold. J. Med. Chem. 2006, 49, 6209-6221.
19. Vassilev, L. T. p53 activation by small molecules: application in oncology. J. Med. Chem. 2005, 48, 4491-4499.
20. Vassilev, L. T. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 2007, 13, 23-31.
21. Shangary, S.; Wang, S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu. Rev. Pharmacol. Toxicol. 2009, 49, 223-41.
22. Shangary, S.; Wang, S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 2008, 14, 5318-5324.